Degenerative Disc Disease (DDD)
-
Biologics
Bone Biologics Receives Human Research Ethics Committee Approval to Begin Pilot Clinical Trial with NB1 in Spinal Fusion Patients in Australia
Company plans to begin 30-patient trial later this year April 11, 2023 BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics Corporation (NASDAQ: BBLG), a…
Read More » -
Financial
Global Degenerative Disc Disease Treatment Market to Surpass US$ 4,525.9 Million by 2030, Says Coherent Market Insights (CMI)
Burlingame, Feb. 13, 2023 (GLOBE NEWSWIRE) — According to Coherent Market Insights, the global degenerative disc disease treatment market is estimated to…
Read More » -
Spine
Bone Biologics Advances Preparations for NB1 Pilot Clinical Trial with Engagement of Contract Research Organization
January 26, 2023 BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces…
Read More » -
Spine
DiscGenics Announces Positive Two-Year Clinical Data from Study of Discogenic Progenitor Cell Therapy for Degenerative Disc Disease
Discogenic progenitor cell therapy safely increased disc volume and provided rapid, durable improvements in low back pain, function, quality of…
Read More » -
Spine
Spinal Stabilization Technologies Ltd. Announces Start of LOPAIN 2 Clinical Trial in South America for Lumbar Degenerative Disc Disease
KILKENNY, Ireland, Nov. 16, 2022 /OrthoSpineNews/ — Spinal Stabilization Technologies (SST) has announced the start of the LOPAIN2 clinical trial of the PerQdisc™…
Read More » -
Spine
Spine BioPharma Announces First Patient Treated in U.S. Phase 3 Clinical Study
SB-01 For Injection Offers New Potential Treatment for Patients Sufferingfrom Chronic Low Back Pain NEW YORK, September 7, 2022 – OrthoSpineNews…
Read More » -
Spine
Spine BioPharma Initiating U.S. Phase 3 Clinical Study
SB-01 For Injection Offers New Potential Treatment for Patients Sufferingfrom Chronic Low Back Pain. New York, NY., May 11, 2022…
Read More » -
Financial
Spine BioPharma Completes Series B Financing
Proceeds Will Support Clinical Advancement of SB-01 For Injection for Treatment of Degenerative Disc Disease NEW YORK, March 28, 2022 /PRNewswire/ — Spine BioPharma, Inc.,…
Read More » -
Spine
Precision Spine® Launches the Dakota ACDF™ Standalone System
September 29, 2021 – Parsippany, NJ /OrthoSpineNews/ – Precision Spine, Inc., a medical device company dedicated to Made-in-the-USA manufacturing, announced…
Read More » -
Spine
Aurora Spine Corporation Announces First Patients in Multicenter Study of ZIP® Interspinous Fixation Device
CARLSBAD, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) — Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF),…
Read More » -
Regulatory
Spinal Stabilization Technologies Ltd Earns CE Mark, FDA “Breakthrough Designation” For PerQdisc Nucleus Replacement System For Degenerative Disc Disease
KILKENNY, Ireland, May 25, 2021 /PRNewswire/ — Spinal Stabilization Technologies, Ltd. (SST), Kilkenny, Ireland announced today that it has earned the CE Mark and the FDA’s…
Read More » -
Biologics
Cerapedics Announces FDA Breakthrough Device Designation Granted for P-15L Bone Graft for the Treatment of Degenerative Disc Disease
– P-15L Bone Graft is currently being studied in the Company’s ASPIRE IDE clinical trial – WESTMINSTER, Colo., April 29, 2021 /PRNewswire/…
Read More » -
Spine
Precision Spine® Receives FDA 510(K) Clearance for the Dakota ACDF™ Standalone System
February 4, 2021 PARSIPPANY, N.J.–(BUSINESS WIRE)–Precision Spine, Inc., a medical device company dedicated to Made-in-the-USA manufacturing, announced today that it…
Read More » -
Regulatory
Aesculap Celebrates Five-Year Anniversary of the FDA Approval of the activL® Artificial Disc: Five Years and Five Milestones
CENTER VALLEY, Pa., June 18, 2020 /PRNewswire/ — Aesculap Implant Systems, LLC today announced that it has been five years since the organization…
Read More » -
Biologics
DiscGenics Announces Completion of Enrollment in U.S. Phase 1/2 Clinical Trial of Discogenic Cell Therapy for Degenerative Disc Disease
SALT LAKE CITY, March 4, 2020 /PRNewswire/ — DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate…
Read More »